IL10 and non-small cell lung carcinoma: By stratifying patients with stage I NSCLC into low and high NPX-based “risk groups” by considering the median NPX value of IL-10 at baseline as a cut-off we observed that differences in IL-10 expression were already present at baseline and seemed not to be affected by SBRT (Figure 5b).